Abstract: The present disclosure relates to detecting one or more types of gynecological cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of gynecological cancer (e.g., cervical cancer, ovarian cancer, endometrial cancer) in a biological sample from a subject having or suspected of having a gynecological cancer.

Abstract: The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent ?-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.

Abstract: A thermostat for a building includes a light emitting diode (LED) system including one or more LEDs configured to emit light to illuminate a floor area beneath the thermostat. The thermostat incorporates an occupancy sensor to sense the approach of a user based on changes in conditions in proximity to the thermostat and detect an ambient light level. The thermostat includes a processing circuit configured to receive data outputs from the occupancy sensor, determine whether the data outputs indicate the approach of a user, cause the one or more LEDs to emit the light towards the floor in response to an indication that a user is approaching the thermostat based on occupancy sensor data correlated with occupancy conditions, and record and store LED activations and deactivations for later retrieval as historic data. The one or more LEDs may be configured as an illumination module removably attachable to the thermostat.

Abstract: A thermostat for a building includes a halo light emitting diode (LED) system including one or more LEDs configured to emit light and a halo diffuser structured around at least a portion of an outer edge of the thermostat. The halo diffuser is configured to diffuse the emitted light of the one or more LEDs around at least the portion of the outer edge of the thermostat. The thermostat includes a processing circuit configured to receive one or more data streams, determine whether the one or more data streams indicate a building emergency condition, and operate the one or more LEDs of the halo LED system to indicate the building emergency condition to a user.

Abstract: The invention relates to commercially viable methods for producing biologically active vitamin K dependent protein, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent ?-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.

Abstract: A thermostat for a building includes a halo light emitting diode (LED) system including one or more LEDs configured to emit light and a halo diffuser structured around at least a portion of an outer edge of the thermostat. The halo diffuser is configured to diffuse the emitted light of the one or more LEDs around at least the portion of the outer edge of the thermostat. The thermostat includes a processing circuit configured to receive one or more data streams, determine whether the one or more data streams indicate a building emergency condition, and operate the one or more LEDs of the halo LED system to indicate the building emergency condition to a user.

Abstract: A thermostat for a building includes a halo light emitting diode (LED) system including one or more LEDs configured to emit light and a halo diffuser structured around at least a portion of an outer edge of the thermostat. The halo diffuser is configured to diffuse the emitted light of the one or more LEDs around at least the portion of the outer edge of the thermostat. The thermostat includes a processing circuit configured to receive one or more data streams, determine whether the one or more data streams indicate a building emergency condition, and operate the one or more LEDs of the halo LED system to indicate the building emergency condition to a user.

Abstract: A thermostat for a building includes a light emitting diode (LED) system including one or more LEDs configured to emit light to illuminate a floor area beneath the thermostat. The thermostat incorporates an occupancy sensor to sense the approach of a user based on changes in conditions in proximity to the thermostat and detect an ambient light level. The thermostat includes a processing circuit configured to receive data outputs from the occupancy sensor, determine whether the data outputs indicate the approach of a user, cause the one or more LEDs to emit the light towards the floor in response to an indication that a user is approaching the thermostat based on occupancy sensor data correlated with occupancy conditions, and record and store LED activations and deactivations for later retrieval as historic data. The one or more LEDs may be configured as an illumination module removably attachable to the thermostat.

Abstract: A thermostat for a building includes a halo light emitting diode (LED) system including one or more LEDs configured to emit light and a halo diffuser structured around at least a portion of an outer edge of the thermostat. The halo diffuser is configured to diffuse the emitted light of the one or more LEDs around at least the portion of the outer edge of the thermostat. The thermostat includes a processing circuit configured to receive one or more data streams, determine whether the one or more data streams indicate a building emergency condition, and operate the one or more LEDs of the halo LED system to indicate the building emergency condition to a user.

Abstract: The invention relates to commercially viable methods for producing biologically active vitamin R dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent ?-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.

Abstract: The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent ?-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.

Abstract: The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent ?-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.

Abstract: A cashless gaming system and method of securely transferring a monetary value. When “cashing-out” of a first terminal of the system, the monetary value is encrypted with an encryption key and an encryption algorithm to produce an encrypted monetary value. A transaction code is associated with encryption key and the monetary value. The transaction code and encrypted monetary value are written to a transportable medium that is issued by the first terminal. The transaction code and associated encryption key are stored in a key repository database. The transaction code and monetary value are stored in an accounting database which is securely separate from the key repository database. The transportable medium is taken to a second terminal where the encrypted monetary value and transaction code are read. The encryption key associated with the transaction code is retrieved and used to decrypt the encrypted monetary value. The monetary value is then credited to the second terminal.

Abstract: An oral compound of water; glycerin; a cranberry source; methylsulfonylmethane; melaleuca alternifolia oil; hydroxyethylcellulose; and a surfactant, in proper combination for use by injecting the compound around a person's gum line followed by its use in a dental tray over a person's teeth and gums for a specified period of time. The next phase to the overall treatment regimen is a daily health care regimen involving: a systemic immune defense compound having colostrum beta 1,3 Glucans; fructo-oligosaccharides; amla fruit 4:1; inositol hexaphosphate; selected minerals; selected enzymes; selected probiotics; and methylsulfonylmethane; an antimicrobial compound having sodium bicarbonate, silicone dioxide, and a cranberry source; and an oral probiotic compound having selected probiotics; vitamin C; and colostrum.

Abstract: An oral compound of water; glycerin; a cranberry source; methylsulfonylmethane; melaleuca alternifolia oil; hydroxyethylcellulose; and a surfactant, in proper combination for use by injecting the compound around a person's gum line followed by its use in a dental tray over a person's teeth and gums for a specified period of time.

Abstract: The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.

Abstract: This invention is directed to the preparation and utilization of supplemented chitin hydrogels, such as chitosan hydrogels. Further provided are biomaterials comprising same. The particular supplement delivered by the chitin hydrogel is selected as a function of its intended use. In one embodiment, this invention provides a composition of matter, comprising a chitin hydrogel or chitin-derived hydrogel, wherein the hydrogel does not inhibit full-thickness skin wound healing.

Abstract: The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.

Abstract: A golf club has a head with a ball contact face and a shaft with surface indicia thereon or on an attachment thereto which may be used to provide for aligning the club face to be in a plane substantially perpendicular to a predetermined ball trajectory. The shaft or attachment may be of rectangular or square cross section with one or two surfaces extending normal to the club face and including contrasting indicia on such surfaces with respect to surfaces which extend parallel to the club face. The shaft may be of circular cross section with contrasting indicia provided on opposite sides of the shaft with respect to a plane through the central axis of the shaft and parallel to the club face, or include a hand grip with a generally flat thumbrest surface with contrasting indicia and extending in a plane perpendicular to the ball contact face.

Abstract: The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.